Hikma Pharmaceuticals (HIK) Stock Overview
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
HIK Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£18.39 |
| 52 Week High | UK£23.60 |
| 52 Week Low | UK£15.78 |
| Beta | 0.63 |
| 1 Month Change | 2.45% |
| 3 Month Change | -5.16% |
| 1 Year Change | -1.82% |
| 3 Year Change | 47.47% |
| 5 Year Change | -29.62% |
| Change since IPO | 552.13% |
Recent News & Updates
Hikma Pharmaceuticals (LON:HIK) Has A Somewhat Strained Balance Sheet
Oct 27
Do Hikma Pharmaceuticals' (LON:HIK) Earnings Warrant Your Attention?
Sep 10Recent updates
Hikma Pharmaceuticals (LON:HIK) Has A Somewhat Strained Balance Sheet
Oct 27Do Hikma Pharmaceuticals' (LON:HIK) Earnings Warrant Your Attention?
Sep 10Earnings Tell The Story For Hikma Pharmaceuticals PLC (LON:HIK)
Aug 02Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Jun 19Investors Appear Satisfied With Hikma Pharmaceuticals PLC's (LON:HIK) Prospects
Apr 08Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Mar 17
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth.Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11Shareholder Returns
| HIK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.9% | 2.0% | 0.6% |
| 1Y | -1.8% | 12.9% | 17.6% |
Return vs Industry: HIK underperformed the UK Pharmaceuticals industry which returned 12.9% over the past year.
Return vs Market: HIK underperformed the UK Market which returned 17.6% over the past year.
Price Volatility
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: HIK has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: HIK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,500 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| HIK fundamental statistics | |
|---|---|
| Market cap | UK£4.07b |
| Earnings (TTM) | UK£282.42m |
| Revenue (TTM) | UK£2.45b |
Is HIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIK income statement (TTM) | |
|---|---|
| Revenue | US$3.22b |
| Cost of Revenue | US$1.83b |
| Gross Profit | US$1.38b |
| Other Expenses | US$1.01b |
| Earnings | US$371.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 43.03% |
| Net Profit Margin | 11.54% |
| Debt/Equity Ratio | 59.0% |
How did HIK perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 21:21 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Mather | Barclays |
| Sidhartha Modi | Barclays |
| Emily Field | Barclays |